(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 22 January 2004 (22.01.2004)

PCT

(10) International Publication Number WO 2004/006801 A3

(51) International Patent Classification⁷: 33/32, 33/06, 31/20, 31/07, 47/00

A61K 35/60,

(21) International Application Number:

PCT/US2003/022297

(22) International Filing Date:

17 July 2003 (17.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/396,222

17 July 2002 (17.07.2002) US

(71) Applicants and

(72) Inventors: THORNTON, Spencer, P. [US/US]; 5070 Villa Crest Drive, Nashville, TN 37220 (US). TROYER, Ellen [US/US]; 3 12th Avenue, San Francisco, CA 94118 (US).

(74) Agents: HARDAWAY, John, B., III et al.; Nexsen Pruet Jacobs & Pollard, LLC, P.O. Box 10107, Greenville, SC 29603 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only

Published:

with international search report

(88) Date of publication of the international search report: $10 \, \text{June} \, 2004$

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT FOR DRY EYE SYNDROME

(57) Abstract: A novel formulation for the treatment of the many underlying inflammatory processes that cause dry eye syndrome. In particular, the formulation, which is orally administered includes the optimal blend of omega-3 and omega-6 essential fatty acids, and nutrient cofactors necessary to enhance the metabolic conversion associated with the tear-specific series E-one anti-inflammatory prostaglandin (PGE1). As used herein, the term "nutrient cofactor" refers to a compound that supports and enhances the conversion of linoleic acid to gamma-linolenic acid. Additionally, the formulation inhibits the production of pro-inflammatory compounds, as well as the growth of viral and bacterial pathogens of the three-layer tear film.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/22297

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 35/60, 33/32, 33/06, 31/20, 31/07, 47/00 US CL : 424/523, 697, 643; 514/558, 912, 915, 725, 777 According to International Patent Classification (IPC) or to both national classification and IPC						
According to International Patent Classification (IPC) or to both hattonal classification and IPC B. FIELDS SEARCHED						
		hy classifi	cation symbols)			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/523, 697, 643; 514/558, 912, 915, 725, 777						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet						
C. DOC	UMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where a	ppropriate,	of the relevant passages	Relevant to claim No.		
Y, P	US 6,506,412 B2 (TROYER et al.) 14 January 200	3 (14.01.20	003), entire document.	1-20		
Y, P	US 2002/0128191 A1 (SCANNON) 12 September 2	2002, entir	e document.	1-20		
Y, P	US 6,537,581 B2 (TAO) 25 March 2003 (25.03.2003), entire document.			1-20		
Y,P	US 6,585,987 B1 (FRANSONI) 01 July 2003 (01.0	7.2003), e	ntire document.	1-20		
Y	US 6,093,706 A (ZELIGS) 25 July 2000 (26.07.2000), entire document.		1-20			
	documents are listed in the continuation of Box C.		See patent family annex.	ametical filing data or priority		
"A" document	pecial categories of cited documents: defining the general state of the art which is not considered to be alar relevance	*T*	later document published after the inte date and not in conflict with the applia principle or theory underlying the inve document of particular relevance; the	cation but cited to understand the cation		
"E" earlier ap	plication or patent published on or after the international filing date	^	considered novel or cannot be considered when the document is taken alone	red to involve an inventive step		
establish specified)		-Y•	document of particular relevance; the considered to involve an inventive ste combined with one or more other suc- being obvious to a person skilled in th	when the document is a document, such combination		
P document	referring to an oral disclosure, use, exhibition or other means t published prior to the international filing date but later than the late claimed	*&*	document member of the same patent			
Date of the actual completion of the international search Date of mailing of the international search report						
18 December 2003 (18.12.2003)						
Name and mailing address of the ISA/US Authorized officer Authorized officer						
Mail Stop PCT, Attn: ISA/US Commissioner for Patents S. Devi Ph.D.						
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703)305-3230 Telephone No. (703) 308-0196						
Facsimile No. (703)303-3230						

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT	
Continuation of B. FIELDS SEARCHED Item 3: WEST, DIALOG, MEDLINE, BIOSIS, EMBASE Dry eye syndrome, omega fatty acid, linolenic acid, lactoferrin, mucin, vitamin?,	curcumin, currant seed, DHEA, inventors

PCT/US03/22297